Actively Recruiting

Age: 20Years - 65Years
All Genders
NCT07388407

Pharmacogenetics of Leflunomide in the Management of Rheumatoid Arthritis

Led by Foundation University Islamabad · Updated on 2026-02-05

110

Participants Needed

2

Research Sites

108 weeks

Total Duration

On this page

Sponsors

F

Foundation University Islamabad

Lead Sponsor

S

Shifa Tameer-e-Millat University

Collaborating Sponsor

AI-Summary

What this Trial Is About

1. Patients taking leflunomide as the only disease-modifying anti-rheumatic drug (DMARD) will be recruited after consent. 2. Blood sample for DNA extraction will be taken The patient will be followed up till two visits 3 months apart, and efficacy and toxicity will be checked using DAS28, ultrasonography, and blood tests for ESR, CRP, anti-CCP, liver function tests, etc. The data form for toxicity will be filled. 3. DNA will be extracted in the laboratory, and SNP will be identified. 4. The efficacy and toxicity data will be studied against the SNPs found 5. An algorithm will be constructed for Pakistani RA patients taking leflunomide.

CONDITIONS

Official Title

Pharmacogenetics of Leflunomide in the Management of Rheumatoid Arthritis

Who Can Participate

Age: 20Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients must meet the revised ACR/EULAR criteria for rheumatoid arthritis at baseline
  • Pakistani individuals
  • Aged between 20 and 75 years
  • New cases started on leflunomide or those taking it for less than one month with available clinical and biochemical data
Not Eligible

You will not qualify if you...

  • Patients not willing to participate or who do not provide consent
  • Patients under 20 years of age
  • Non-Pakistani individuals
  • Taking another DMARD simultaneously
  • Having compromised kidney or liver function
  • Cognitive impairment or neurological disease
  • Pregnant or lactating women
  • Patients with inflammatory bowel disease or irritable bowel syndrome
  • Patients with active infections
  • Patients who do not complete 3 months of leflunomide therapy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Shifa International Hospital

Islamabad, Punjab Province, Pakistan, 44000

Completed

2

Fauji Foundation Hospital, Rawalpindi

Rawalpindi, Punjab Province, Pakistan, 46000

Actively Recruiting

Loading map...

Research Team

D

Dr. Zarafshan Bader, MPhil, MBBS

CONTACT

D

Dr Abida Shaheen, PHD, MBBS, FAIMER FELLOW

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here